Last updated: July 20, 2026
Ashwagandha (Withania somnifera) is one of the most-studied adaptogenic herbs on the supplement market, and KSM-66 is the specific, standardized root extract used in a majority of the modern human trials. This article walks through what the actual published research says about KSM-66 and stress-related markers like self-reported stress, anxiety symptoms, sleep, and serum cortisol — along with the limits of that research and who should be cautious. Nothing here is a claim that ashwagandha treats, cures, or prevents any disease; the language below intentionally stays in “may support” territory because that is what the evidence base currently allows.
What is KSM-66?
KSM-66 is a trademarked, full-spectrum root-only extract of ashwagandha, standardized to a defined withanolide content and produced without the use of alcohol in extraction. It is one of the more heavily researched proprietary ashwagandha extracts, which matters because “ashwagandha” as a category covers many different extraction methods, plant parts (root vs. leaf vs. root+leaf), and withanolide concentrations — results from one extract don’t automatically transfer to another. When you’re comparing studies, checking whether the study used KSM-66 specifically (versus a generic or different branded extract) is a meaningful detail, not a technicality.
The core human trials
Chandrasekhar et al., 2012 (Indian Journal of Psychological Medicine, PMID 23439798). This is the most frequently cited KSM-66 trial. It was a randomized, double-blind, placebo-controlled study in 64 adults with a history of chronic stress, given either 300 mg of high-concentration full-spectrum ashwagandha root extract twice daily or placebo for 60 days. The ashwagandha group showed significantly greater reductions on the Perceived Stress Scale (PSS) and other stress and anxiety questionnaires compared to placebo, and serum cortisol levels were reduced by roughly 27.9% in the treatment group versus a much smaller change in placebo. This is a reasonably solid early trial, but the sample size is modest and it is a single study from one research group.
Lopresti, Smith, Malvi & Kodgule, 2019 (Medicine (Baltimore), PMID 31517876). A 60-day randomized, double-blind, placebo-controlled trial in 60 adults with self-reported high stress, comparing 240 mg/day of a standardized ashwagandha extract to placebo. The treatment group showed significant improvements in self-reported stress and anxiety scores, sleep quality, and food cravings, along with a significant reduction in morning serum cortisol relative to placebo. This trial also measured DHEA-S and testosterone changes, which is a reminder that ashwagandha’s studied effects extend beyond stress markers alone — another reason to talk to a doctor before combining it with hormone-related medications or conditions.
Salve, Pate, Debnath & Langade, 2019 (Cureus, PMID 31728244). A double-blind, randomized, placebo-controlled study in 60 healthy adults given 300 mg of ashwagandha root extract twice daily for 8 weeks. Researchers reported significant improvements in stress-related outcome measures (including PSS and other stress/anxiety scales) and improved sleep quality scores in the treatment group compared to placebo, with good tolerability.
Auddy et al., 2008 (Journal of the American Nutraceutical Association). An earlier, smaller placebo-controlled study reporting reductions in serum cortisol and improvements in stress-related symptom scores over 60 days of ashwagandha extract supplementation in chronically stressed adults. It is frequently cited as early supporting evidence but predates the larger, better-designed trials above.
What this body of evidence adds up to — and doesn’t
Taken together, these trials consistently point in the same direction: in adults reporting chronic or elevated stress, 8–12 weeks of standardized ashwagandha root extract supplementation is associated with lower self-reported stress and anxiety scores and, in several trials, measurably lower serum cortisol compared to placebo. That consistency across multiple independent research groups is meaningfully more convincing than any single trial on its own.
That said, honest limitations matter:
- Sample sizes are small. Most of these trials involve 60–64 participants — enough to detect a signal, not enough to rule out variability across different populations.
- Trial duration is short. Most studies run 8–12 weeks. We don’t have strong long-term (6-12 month+) data on sustained use.
- Populations are narrow. Many trials specifically recruited adults who self-identified as having chronic stress, which is not the same as the general population, and results may not generalize to everyone.
- Funding and author overlap. A number of the KSM-66-branded trials involve authors and funding connected to the extract’s manufacturer, which doesn’t invalidate the data but is a relevant disclosure to weigh, per standard practice recommended by NIH NCCIH when evaluating supplement research.
- Cortisol is one biomarker, not a diagnosis. A change in serum cortisol under controlled trial conditions is not the same as treating a stress disorder, adrenal condition, or any diagnosed illness.
For a plain-language overview from a federal source, the NIH’s National Center for Complementary and Integrative Health maintains a fact sheet on ashwagandha’s studied uses, dosing ranges seen in research, and safety considerations — a useful starting point alongside the primary trials above.
Sleep and mood: a related but separate body of research
Several of the same research groups that studied ashwagandha for stress have also published double-blind, placebo-controlled trials specifically on sleep quality (for example, Langade et al., Cureus, on ashwagandha root extract in adults with insomnia and anxiety), generally finding improvements in subjective sleep quality and sleep onset latency versus placebo over several weeks. Stress and sleep are physiologically intertwined, so it’s not surprising the same extract shows effects in both areas — but sleep-specific claims should rest on the sleep-specific trials, not be inferred loosely from the stress trials alone.
Cautions
Ashwagandha is generally well tolerated in the published trials at studied doses (commonly 240–600 mg/day of standardized extract), with the most frequently reported side effects being mild gastrointestinal upset or drowsiness. But there are real reasons for caution, and this is not a complete medical list:
- Thyroid conditions:
- Pregnancy and breastfeeding: ashwagandha is traditionally contraindicated in pregnancy in some sources, and there isn’t robust modern safety data for pregnant or breastfeeding people. Avoid unless a physician advises otherwise.
- Autoimmune conditions: because ashwagandha may modulate immune activity, people with autoimmune diseases (e.g., rheumatoid arthritis, lupus, Hashimoto’s) should consult a doctor first.
- Liver health: there are published case reports of liver injury temporally associated with ashwagandha use, and some regulatory bodies (including health authorities outside the US) have flagged this as a signal worth monitoring. Anyone with existing liver disease, or who develops symptoms like jaundice, dark urine, or unusual fatigue while taking it, should stop and see a doctor.
- Sedatives and blood pressure/thyroid/immunosuppressant medications: ashwagandha may interact with these drug classes; check with a pharmacist or physician before combining.
- Surgery: because of possible sedative and immune effects, it’s commonly recommended to stop ashwagandha at least two weeks before scheduled surgery.
- Not a substitute for care: ashwagandha research measures statistical changes in group averages under trial conditions. It is not a treatment for clinical anxiety, depression, or endocrine disorders, and nothing here should replace evaluation by a licensed clinician for those conditions.
As always, quality and dose matter — look for a product that states the specific extract (e.g., KSM-66) and the standardized withanolide content, rather than a generic “ashwagandha” label with no extraction or standardization details.
The bottom line
Multiple independent, randomized, placebo-controlled human trials — Chandrasekhar 2012, Lopresti 2019, Salve 2019, and earlier work by Auddy — consistently report that standardized ashwagandha root extract supplementation over 8–12 weeks is associated with lower self-reported stress and anxiety scores, and in several trials, reduced serum cortisol, compared to placebo. This is genuinely one of the better-supported adaptogen categories in the supplement world, but the trials are still relatively few, small, and short-term, so “may support a healthy stress response” is the honest framing — not a guarantee, and not a substitute for medical care when stress, anxiety, or sleep problems are significant or persistent.
If you want to try a standardized extract for yourself, NutriPeak carries a KSM-66 ashwagandha formula dosed in the range studied in the trials above — worth a look if you’re deciding what to check the label for regardless of where you buy.
This article is for educational purposes and is not medical advice. Talk to a healthcare provider before starting any supplement, especially if you are pregnant, nursing, managing a chronic condition, or taking medication.